Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension

Advances in Experimental Medicine and Biology

Volumn 661, Issue , 2010, Pages 419-434

  Moreno Vinasco, Liliana ^a   Garcia, Joe G N ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Caldesmon; Cytoskeleton; Endothelium; Sorafenib; Vascular remodeling

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CALDESMON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MYOSIN LIGHT CHAIN KINASE; SEMAXANIB; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA3; VASCULOTROPIN RECEPTOR 2; BENZENESULFONIC ACID DERIVATIVE; CALMODULIN BINDING PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOINFORMATICS; CELL PROLIFERATION; CONFERENCE PAPER; CYTOSKELETON; DNA MICROARRAY; DRUG DESIGN; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; HUMAN; LUNG ARTERY; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; LUNG VASOCONSTRICTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; RODENT; VASODILATATION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; HEMODYNAMICS; LUNG; METABOLISM; MICROARRAY ANALYSIS; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION; VASCULARIZATION;

RODENTIA;

ANIMALS; BENZENESULFONATES; CALMODULIN-BINDING PROTEINS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; LUNG; MICROARRAY ANALYSIS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 77951212413     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60761-500-2_27     Document Type: Conference Paper

References (28)

1. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML et al (2008) Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 33:278-291 (Pubitemid 351629535)
2. Higenbottam T, Cremona G (1993) Acute and chronic hypoxic pulmonary hypertension. Eur Respir J 6:1207-1212 (Pubitemid 23297939)
3. Moudgil R, Michelakis ED, Archer SL (2005) Hypoxic pulmonary vasoconstriction. J Appl Physiol 98:390-403 (Pubitemid 40041273)
4. Taraseviciene-Stewart L, Kasahara Y, Alger L et al (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15:427-438 (Pubitemid 32141434)
5. Raiesdana A, Loscalzo J (2006) Pulmonary arterial hypertension. Ann Med 38:95-110
6. Rhodes CJ, Davidson A, Gibbs JS, Wharton J, Wilkins MR (2009) Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 121:69-88
7. Adatia I (2002) Recent advances in pulmonary vascular disease. Curr Opin Pediatr 14:292-297 (Pubitemid 34478516)
8. Bull TM, Coldren CD, Nana-Sinkam P et al (2005) Microarray analysis of peripheral blood cells in pulmonary arterial hypertension, surrogate to biopsy. Chest 128:584S (Pubitemid 43054141)
9. Geraci MW, Gao B, Hoshikawa Y, Yeager ME, Tuder RM, Voelkel NF (2001) Genomic approaches to research in pulmonary hypertension. Respir Res 2:210-215 (Pubitemid 34187928)
10. Girgis RE, Li D, Zhan X et al (2003) Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 285:H938-H945 (Pubitemid 37048146)
11. Girgis RE, Ma SF, Ye S et al (2005) Differential gene expression in chronic hypoxic pulmonary hypertension: effect of simvastatin treatment. Chest 128:579S (Pubitemid 43054134)
12. Bull TM, Coldren CD, Moore M et al (2004) Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. Am J Respir Crit Care Med 170:911-919 (Pubitemid 39359232)
13. Budhiraja R, Tuder RM, Hassoun PM (2004) Endothelial dysfunction in pulmonary hypertension. Circulation 109:159-165 (Pubitemid 38114133)
14. Archer SL, Michelakis ED (2006) An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol 21:385-392 (Pubitemid 44315072)
15. Grant SK (2009) Therapeutic protein kinase inhibitors. Cell Mol Life Sci 66:1163-1177
16. McLaughlin VV, McGoon MD (2006) Pulmonary arterial hypertension. Circulation 114:1417-1431 (Pubitemid 44454562)
17. Klein M, Schermuly RT, Ellinghaus P et al (2008) Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 118:2081-2090
18. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109 (Pubitemid 39331023)
19. Rahmani M, Davis EM, Bauer C, Dent P, Grant S (2005) Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 280:35217-35227 (Pubitemid 41532709)
20. Rahmani M, Davis EM, Crabtree TR et al (2007) The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 27:5499-5513 (Pubitemid 47124402)
21. Rahmani M, Nguyen TK, Dent P, Grant S (2007) The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol 72:788-795 (Pubitemid 47351213)
22. Grant S (2008) Cotargeting survival signaling pathways in cancer. J Clin Invest 118: 3003-3006
23. Gharib SA, Luchtel DL, Madtes DK, Glenny RW (2005) Global gene annotation analysis and transcriptional profiling identify key biological modules in hypoxic pulmonary hypertension. Physiol Genomics 22:14-23 (Pubitemid 41356334)
24. Malek RL, Wang HY, Kwitek AE et al (2006) Physiogenomic resources for rat models of heart, lung and blood disorders. Nat Genet 38:234-239 (Pubitemid 43177240)
25. Mirzapoiazova T, Kolosova IA, Romer L, Garcia JG, Verin AD (2005) The role of caldesmon in the regulation of endothelial cytoskeleton and migration. J Cell Physiol 203:520-528 (Pubitemid 40629014)
26. Dudek SM, Garcia JG (2001) Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol 91:1487-1500 (Pubitemid 32900340)
27. Phillips PG (1994) Thrombin-induced alterations in endothelial cell cytoarchitectural and functional properties. Semin Thromb Hemost 20:417-425 (Pubitemid 24381851)
28. Phillips PG, Lum H, Malik AB, Tsan MF (1989) Phallacidin prevents thrombin-induced increases in endothelial permeability to albumin. Am J Physiol 257:C562-C567